Step into a whole new world with one of the largest global platforms dedicated to immersive virtual and augmented reality content, Littlstar. Yahoo Finance's Adam Shapiro and Julie Hyman discuss with the company's CEO Tony Mugavero.
Step into a whole new world with one of the largest global platforms dedicated to immersive virtual and augmented reality content, Littlstar. Yahoo Finance's Adam Shapiro and Julie Hyman discuss with the company's CEO Tony Mugavero.
French luxury house Chanel on Wednesday lost its trademark fight with Huawei Technologies after a top European court said their logos bear no similarity to each other. The dispute dated to 2017 when Huawei sought approval from the EU Intellectual Property Office (EUIPO), a trademark body, to register its computer hardware trademark which has two vertical interlocking semi-circles. Privately owned Chanel objected, saying that the design was similar to its registered French logo of two horizontal interlocking semi-circles used for its perfumes, cosmetics, costume jewellery, leather goods and clothing.
(Bloomberg) -- The Australian dollar may climb to 85 U.S. cents within a year as commodity prices hold firm and the greenback retreats, according to the currency’s top forecaster.The Aussie is on track to recapture the 80 cents handle in the coming months, with the dollar expected to weaken as U.S. exceptionalism fades, said Ray Attrill at National Australia Bank Ltd., the most accurate Aussie forecaster in the first quarter in Bloomberg rankings.“This is a view heavily contingent on commodity prices remaining firm, risk sentiment holding up, and a related softening in the dollar,” Attrill said.The bets on the Aussie reflect confidence that the global economy is on the mend as commodities ranging from oil to iron ore push higher on signs of a recovery in demand. But not everyone shares that optimism, with asset managers extending short positions on the currency into a fourth week as at mid-April.The Aussie traded around 77 cents on Thursday and last reached the 85 mark in December 2014.The main risk to NAB’s call is if the renewed spike in virus cases “extends to a new infection wave in Europe, which runs ahead of rising vaccination rates and necessitates fresh large-scale economic lockdowns,” Attrill said.“Unless or until this risk eventuates, we continue to view any dips in AUD/USD back to the early April lows beneath 0.76 as buying opportunities,” he said.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
The two bidding companies are locking horns to take control of a vast network of railways across North America, with Canadian National offering to buy Kansas City Southern in a $33.7 billion deal that trumped Canadian Pacific's $25 billion bid. Canadian Pacific had on Tuesday called the opposing offer "illusory and inferior", flagging its complex nature and saying it would reduce competition and negatively impact shippers. "I just frankly don't believe that's the right value proposition for our shareholders to put our balance sheet at risk, to use all of our capacity in our power to take our ability to respond with shocks to the market," Creel said in a post-earnings call with investors.
Reopening plays like airlines fell, with shares of Qantas Airways in Australia dropping 1.7% while ANA Holdings in Japan declined 1.45%.
Pernod Ricard said on Thursday it expected 10% organic profit growth in fiscal year 2020/21 after strong demand in its key U.S. and Chinese markets helped the French spirits group beat third quarter sales forecasts. The owner of Mumm champagne, Absolut vodka and Martell cognac expected sales to accelerate in the fourth quarter as bars and restaurants gradually reopen, though travel retail is expected to remain subdued due to limited passenger traffic. That performance marked a return to sales growth after the previous two quarters showed a decline.
(Bloomberg) -- The battery materials unit of SK Innovation Co. said the global market for premium wet-type separators, a key component for electric vehicles, will run into a supply shortage in 2023 due to “explosive” growth.SK IE Technology Co. said in a statement Thursday that its sales of separators for EVs jumped 490% last year from 2018. The company -- part of South Korea’s third-largest conglomerate SK Group -- expects separators will account for about 80% of total sales in the next three years or more, from about 55% currently.“We’ve been keeping a close track of demand and supply and it looks like supply will fall short of meeting the rising demand from 2023,” Chief Executive Officer Rho Jae-sok told reporters at a briefing in Seoul.Separators improve the output and stability of lithium-ion batteries. Wet separators are thinner and stronger than dry separators, and allow for higher capacity. While lithium-ion batteries are found in everything from laptops to cell phones, it’s their primary role in electric vehicles that’s creating surging demand.EV LatecomerSK Innovation has grown into a major industry supplier. Among peers that produce wet-type separators for EVs such as Japan’s Asahi Kasei Corp. and Toray Industries Inc., SK took the biggest market share last year with 26.5%, according to the statement, citing SNE Research Inc. It expects to more than double its annual separation capacity to 2.73 billion square meters in 2024 -- equivalent to supplying 1 million EVs per year.SK was a relative latecomer to the electric-car battery industry, embracing the technology only as part of a diversification push. SK Innovation began developing lithium-ion batteries for hybrid electric vehicles in 2005, and spun off SK IE Technology in April 2019. SK IE Technology plans to go public next month.While the near-term growth will remain in its separator business, the company said it plans to develop materials for solid-state batteries -- a new way of making batteries that experts think could take over from the current generation of lithium-ion cells -- and also expand its production of polyimide film that goes on flexible displays.“It’ll have to be after 2030 when the solid-state battery business gets commercialized, which means lithium-ion batteries will co-exist for some time,” Roh said. “Our parent SK Innovation is also looking into start-up firms with the relevant technologies to explore the areas we can take part in.”SK is not looking beyond China, Europe and the U.S. in expanding its production capacity for now, Roh said. He said the company won’t consider building a facility in America until after 2024, as demand there is currently small compared with China and Europe and the investment and operating costs are more expensive.The company said last month it’s investing 1.1 trillion won ($987 million) to build new factories in Poland to meet growing demand amid an EV boom in Europe.IPO PlansSK IE Technology seeks to raise as much as 2.3 trillion won in its initial public offering. If the stock is priced at the top of the range, it would give the company a market value of around 7.5 trillion won. The company will start trading on Kospi from May 11 after setting the IPO price on April 26. The sale of new shares will go into SK’s capital expenditure until 2023, as it will need between 700 billion and 800 billion won annually, Roh said.SK posted an operating profit of 125 billion won last year, up more than 55% from April-December in 2019 when the company was spun off, while sales rose 78% to 469.3 billion won during the same period. SK’s three-year compound annual growth rate is forecast at 38%, according to Horace Chan, a Bloomberg Intelligence analyst.Rho said SK Innovation’s $1.8 billion settlement earlier this month with LG Energy Solution, a unit of LG Chem Ltd., over trade secrets removed uncertainties and created an environment where the two companies can actively engage in talks about new product models and plans to gradually increase supply. LG is one of SK’s customers in South Korea.(Updated with CEO comment from third paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
The owner of the MailOnline site alleges the search engine has hidden links to its coverage on certain topics.
Nasdaq Inc on Thursday said it was launching options on the Nasdaq-100 Micro Index as a lower-cost way for retail investors to gain exposure to the popular Nasdaq 100 Index. Retail investors have entered the securities markets in droves over the past year as large retail brokers have dropped trading commissions, coronavirus lockdowns forced people to work from home, and as "meme stocks," like GameStop Corp and AMC Entertainment, soared in value in January. "Option investor engagement is at an important inflection point, with newer participants embracing the options market like never before," said Greg Ferrari, head of U.S. options for Nasdaq.
Just what can you invest in with a Roth IRA? And what constitutes a prohibited transaction? Here's what you need to know.
(Bloomberg) -- Daniel Dines struggled with life in the U.S. after leaving his native Romania in 2001 to work for Microsoft Corp., but the experience created the foundation for one of the world’s biggest fortunes.The software programmer returned to his homeland in 2005 to start the business known today as UiPath Inc., an automation-software maker that debuts Wednesday after raising $1.3 billion in a U.S. initial public offering. Dines, the company’s chief executive officer, controls a stake worth more than $6 billion, according to data compiled by Bloomberg.“For someone coming in his 20s to the U.S. from Europe, it was a big challenge for me to adapt to the States, even though professionally speaking my experience at Microsoft was great,” Dines, 49, said last year at the annual Montgomery Summit technology conference.As a result, “I had a crazy idea to go back and start a company,” he added.‘Hidden Advantage’UiPath, which was valued at $7 billion in 2019, is now worth about $30 billion after its shares priced at $56, above a marketed range. That puts Dines among the world’s 500 richest, according to the Bloomberg Billionaires Index. A company representative declined to comment.“Starting a company from a small place with no market has a hidden advantage: It forces you to think globally from day one,” Dines said in a letter included in UiPath’s registry filings for its listing. He had already indicated his company was preparing for a listing back in early 2020.The company’s software performs many low-skilled tasks that businesses once outsourced to humans in cheaper-wage countries such as India or the Philippines. Known as robotic process automation technology, the technique takes over repetitive, routine data-entry and processing tasks. Some of its software has been used in hospitals and health-care projects to help with Covid-19, according to UiPath’s website.Dines, who studied math and computer science at the University of Bucharest, grew up in Romania while the nation was still ruled by dictator Nicolae Ceausescu. He founded the company as DeskOver and renamed it UiPath in 2015, running it out of an apartment in the capital before relocating its headquarters to New York in 2017.Funding RoundUiPath raised $750 million in a funding round led by Alkeon Capital and Coatue that gave it a value of $35 billion, according to a February statement. Altimeter Capital Management, Dragoneer, IVP, Sequoia Capital, Tiger Global Management and funds advised by T. Rowe Price Associates also chimed in.Dines owns all of the company’s Class B shares, which carry 35 votes apiece compared with one each for Class A stock. He will continue to control UiPath after the IPO and sold shares in the offering worth about $75 million, according to filings.“You have to become a public company at some point to allow your employees to get more liquidity, give them stock options,” he said in an interview with Bloomberg last year. “We’re almost there.”(Adds details of share sale in penultimate paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Searches for the phrase, 'When is the housing market going to crash?' are up 2,450% over the past month.
(Bloomberg) -- There’s a slice of the Thai yield curve for everyone.Local investors are bidding up shorter-dated bonds as the spread of Covid-19 in the country convinces them to seek out the safest assets. Global funds are buying longer maturities after the yield premium over Treasuries improved and on the prospect of baht gains.Demand for both ends of the curve -- along with stabilizing U.S. Treasuries -- has helped Thailand’s debt begin to turn around after a poor start to the year. Benchmark 10-year yields have dropped more than 20 basis points to 1.90% from their peak in March, while five-year yields have declined about the same amount to 1%.“Local investors have been shortening duration due to abundant onshore liquidity and to avoid the risk of mark-to-market losses in the event of rebounding yields,” said Poon Panichpibool, a strategist at Krung Thai Bank Pcl in Bangkok.“Foreigners have been extending duration in April due to attractive Thai spreads over Treasuries, and expectations for baht appreciation as is seen from increasing short dollar calls from research houses,” he said.Thailand reported a record one-day virus tally on Friday, spurring the government to impose additional curbs including bans on some alcohol sales and the closure of schools. The rising case count looks set to delay plans to further reopen the borders to much-needed tourism.Local investors have reacted to climbing cases by shifting funds to shorter-dated government debt and away from company bonds. The spread between an index of corporate bonds over sovereign securities widened to 436 basis points this week, the highest in least 10 years, from around 300 basis points before the pandemic.Longer EndForeigners are more interested in the other end of the curve.The decline in Thai bonds earlier this year saw the extra yield offered by 10-year debt over similar-maturity Treasuries climb to more than 30 basis points, after being almost 40 basis points below them early last year. In contrast, the premium on Indonesian bonds over Treasuries has narrowed in the same period.Two more positive factors are are encouraging both local and foreign investors: the central bank’s management of bond supply and the outlook for inflation. Bank of Thailand has greatly reduced issuance of central bank debt since November to accommodate the government’s larger-than-usual financing needs, DBS Bank Ltd. said in a note.The emergence of the third virus wave is likely to damp inflationary pressures due to declining consumer and business confidence, limits on economic activity and lower labor productivity, said Kobsidthi Silpachai, head of capital market research at Kasikornbank Pcl in Bangkok.Picking the next direction for global markets looks to be getting harder than ever amid uncertainties over the pandemic. Nevertheless, the outlook for Thai bonds has been getting brighter - irrespective of which end of the curve you look at.(Updates with central bank’s debt management strategy in 10th paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
It seems that all year I’ve been warning about valuations being out of whack with reality, especially in small-cap tech, which includes most SPACs. SPACs are being slammed as former “diamond hands” turn into weak-handed sellers who are (rightly, in most cases) trying to stop losses that are piling up in their portfolios. Speaking of SPACs, the markets are still suffering from SPAChaustion and a Coinbase Overhype Top, as I’ve also been saying for a few weeks now.
(Bloomberg) -- Intel Corp. ducked getting hit with another multibillion-dollar damage award after a federal jury in Texas cleared it of claims it was infringing patents formerly owned by NXP Semiconductors NV on ways to speed up computers.Intel doesn’t infringe two patents owned by closely held VLSI Technology LLC, according to the federal jury in Waco, Texas. The trial was held in the same courthouse where a different jury told Intel to pay VLSI $2.18 billion over other patents last month.This was the second of three trials in suits VLSI lodged against Intel over patents that until early 2019 were owned by Dutch chipmaker NXP Semiconductors. A third trial, also before U.S. District Judge Alan Albright, is scheduled to begin in June.In the most recent trial, VLSI was seeking $3 billion in damages, saying the inventions were critical to Intel’s ability to make chips faster and with fewer energy requirements. That’s more than 3,000 times what the patents were valued at in past acquisitions, Intel’s lawyers argued.Intel denied using any of the inventions, saying its own engineers have spent decades developing the chips that are used in everything from laptops to military fighter planes. It also argued that the patents didn’t cover new ideas even two decades ago, when they were issued.Intel said in a statement that it was pleased the jury “rejected VLSI’s meritless claims that Intel’s cutting-edge processors infringe expired patents on MP3 player technology.”VLSI was seeking damages for a period beginning March 1, 2019, just before the suit was filed. One of the patents, issued in 2002, expired in November; while the other was issued in 2003 and expires in May, according to data compiled by Bloomberg Law.Intel reported $20.9 billion in net income on $77.9 billion in revenue last year.VLSI was created in 2016 by the Softbank Group Corp.-owned Fortress Investment Group, according to an antitrust lawsuit Intel and Apple Inc. filed against Fortress. Fortress has “deployed patents in waves of lawsuits against their targets without regard for the merits of the claims,” Intel and Apple said in the complaint, which is pending in federal court in California.A federal judge had initially tossed the antitrust case, but Apple and Intel amended their complaint a week after the $2.18 billion verdict, arguing that trial and VLSI’s demand for billions more over other patents is evidence of Fortress’s anticompetitive activities. Fortress is scheduled to respond by April 26.Intel said the cases show the need for legislation “to prevent such ‘litigation investors’ and their shell companies from using low-quality purchased patents to extract exorbitant damages from productive American businesses.”VLSI has no products and its only potential revenue is its litigation against Intel. VLSI lawyer Morgan Chu of Irell & Manella told the jury not to be distracted by that issue.“This was technology that had looked over the horizon, changed the way Intel designed their chips,” Chu told the jurors in closing arguments. The damages request “is a large number but it’s a large number because Intel is the dominant company selling this infringing product.”The patents originated with SigmaTel Inc., which was bought by Freescale Semiconductor Inc. for $110 million in 2008, which in turn was bought by NXP in 2015 in a $12 billion deal. In Freescale’s purchase, SigmaTel’s “intangible assets,” which included a portfolio of hundreds of patents, were valued at $7 million, said Intel lawyer William Lee of WilmerHale in Boston.VLSI brought “unfair and unfounded claims that were created for litigation, and a $3 billion claim that was created for by a paid-for expert,” Lee said in closing arguments, calling the damages demand “objectively unreasonable.”NXP isn’t a party to the case, though in the first trial Lee said that the chipmaker would receive a cut of any damage award. The Eindhoven, Netherlands-based company said it doesn’t comment on ongoing litigation as a matter of corporate policy.During the trial, Intel witnesses highlighted the Santa Clara, California-based company’s long history in developing the chips that power devices that have transformed all aspects of society, and its efforts for the next generation of electronics.Intel has announced billions of dollars in spending on new factories and creating a foundry business to make chips for other companies, part of an aggressive push to regain its manufacturing lead. The move has the support of the Biden administration, which is calling for more U.S.-based chip manufacturing as a result of a global shortage of computer chips caused in part by the pandemic and the world’s reliance on two Asian companies.The patents were the subject of litigation between SigmaTel and Chinese chipmaker Actions Semiconductor Co. in a dispute that settled in 2007. The only other litigation involving these patents are the lawsuits against Intel, Bloomberg Law data show.The case is VLSI Technology LLC. v. Intel Corp., 21-299, U.S. District Court for the Western District of Texas (Waco).(Updates with Intel comment in 6th and 11th paragraphs.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Some Americans who received a federal tax break on their unemployment last year may have to file an amended return to get their refund.
Bitcoin is setting up for a near-term downturn that could see it shed a good chunk of its recent gains, even if the longer-term outlook appears healthy for the world's No. 1 crypto.
It was a dollar or bust for the dogecoin community on Wednesday --- and now it seems as if dogecoin fanatics are just left with the bust. However, a failed attempt at producing an epic rally in doge doesn't seem to have deflated the staunchest supporters of the parody coin.
A deep freeze that swept parts of the United States last quarter knocked out nearly half of Texas power plants and sent prices for natural gas and electricity to record levels. Kinder Morgan benefited from the shortage as it released gas and sold electricity at prices that were hundreds of times higher than normal for several days.
(Bloomberg) -- A slide in the rupee is exacerbating a slump in Indian corporate dollar notes that are now among the worst performers in Asia, just as concerns mount that companies are hedging less.The securities have lost about 0.1% in April, worse than a 0.4% gain for a broader Asian dollar bond gauge, according to a Bloomberg Barclays indexes. All the other countries in Asia have posted positive returns, except China which lost about 0.4% after the stumble by China Huarong Asset Management Co.The weaker rupee pushes up servicing costs on foreign debt. The currency has plunged about 2.4% against the dollar this month, making it Asia’s worst-performer. Spiking Covid-19 cases threaten to worsen the selloffAbout 5 out of 10 Indian firms hedge their foreign borrowings in India as compared to about 8 several years ago before the RBI eased rules on hedging, said Samir Lodha, chief executive officer at QuantArt Market Solutions, a Mumbai-based advisory firm. “The drop in the rupee this month may prompt more local companies with foreign borrowings to consider at least some low-cost hedging.”Primary Market -- Foreign Borrowings SlowThe weaker rupee is also making borrowers hesitate to tap what would otherwise be some of the lowest borrowing costs ever in the dollar bond market. Just one Indian company has settled a note this month: a $585 million deal from ReNew Power. That leaves issuance set for the lowest in six monthsLocal firms have also shunned foreign-currency loans in April after borrowings of $7.2 billion in the previous quarter“Most corporates will definitely pause their plans to issue fresh foreign-currency debt as they wait for the rupee to stabilize,” said Abhishek Goenka, founder of IFA Global, a Mumbai-based advisory firm. “Pandemic-induced currency volatility is making it difficult for borrowers to assess their foreign debt costs.”Firms may be turning more to the local credit market, even though there have been fresh obstacles there tooThey sold 47.6 billion rupees of bonds this week and still plan as much as 80.5 billion rupees more. If all those sales go through, that would be higher than in the previous two weeks combinedStill, offerings have fallen to 139.9 billion rupees ($1.9 billion) this month, the slowest start to a financial year since 2014. That’s due in part to rules that took effect April 1 strengthening the role of trustees for secured bonds backed by assetsSecondary Market -- Sovereign Rating ConcernsThe latest wave of coronavirus infections is also bad for India’s sovereign rating. The country has the lowest investment-grade score with a negative outlook at Moody’s Investors Service and Fitch Ratings“We expect a repeat of 2020’s sudden crash in economic activity in the coming months,” said Timothy Wee Lee Tan and Jason Lee, Bloomberg Intelligence analysts. “With a downgraded GDP growth outlook for FY22, India’s debt burden will be higher than the current IMF forecast, implying an elevated risk of ratings falling into speculative grade.”Any official gross domestic product downgrade may lead to pre-emptive widening of the option-adjusted spread for Indian dollar credits, with an actual offshore sovereign rating downgrade likely to push premiums up to 90 basis points wider to trade closer to Brazil and South Africa, according to Bloomberg IntelligenceDistressed Debt - ARC Rules Under ReviewReserve Bank of India formed a six-member panel Monday to review rules for Asset Reconstruction Companies or ARCs, which help India’s banking system deal with one of the world’s worst bad loan ratios among major economiesARCs have been in the spotlight in recent weeks:Mar. 18: India’s Ministry of Corporate Affairs is investigating allegations of financial irregularities at the asset reconstruction arm of Edelweiss Financial Services Ltd., according to people with direct knowledge of the matter. Edelweiss said it hasn’t received any intimation of any inspection by the ministryMar. 14: India’s central bank has rejected Yes Bank Ltd.’s proposal to set up an ARC for acquiring bad loans on conflict of interest concerns, Mint reported citing people it didn’t identifyMeanwhile, Infrastructure Leasing & Financial Services, whose default in 2018 triggered a prolonged credit crisis in the country, plans to resolve 500 billion rupees ($6.6 billion) of its debt by the end of September, Chairman Uday Kotak said last week. Investors are closely watching the debt resolution as a test case for group insolvencyKotak, who is heading the IL&FS board after government seized control of the shadow lender in 2018, expects to resolve about 62% of its 1 trillion rupees of debtAnother group facing challenges in servicing its debt is Future Group. The Indian supermarket-operator Future Retail Ltd. approved a debt resolution plan that eases some immediate concerns as a legal battle with partner Amazon.com Inc. threatens to delay an asset sale to Reliance Industries Ltd. India’s top court scheduled a final hearing in the matter to May 4Best and Worst Performing Corporate Dollar Bonds Last 12 MonthsFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
The long-term upward trend in the markets is marked; the S&P 500 is up 51% over the last 12 months, even taking into account some recent slips. For investors, this makes the present a propitious time to seek out low-cost market segments with high return potential. Or in other words, to take the old time advice and buy low to sell high. Jefferies equity strategist Steven DeSanctis, in a recent note on small-cap market themes, points out that this segment is attracting investor notice. "We are seeing interest in the size segment and hearing that institutional investors are really interested in adding assets to the size segment. This makes sense to us, as small caps as a percentage of total US equity market exposure is still running well below its 90- year history as investors clamored for large caps, large growth, and the FAANG names. We estimate over $38B has come into small caps over the last five months, the largest inflow since we started tracking the data back to 2006, representing 4.6% of total assets, close to an all-time high. We also estimate about 45% of all flows go towards passive investing, and this drives the performance," DeSanctis wrote. And this brings us to penny stocks, those low-cost equities priced below $5 per share – are a high-stakes opportunity with upsides that frequently approach several hundred percent and a low enough cost of entry to mitigate the attendant risk. These stocks are priced low for a reason, but for those that break out, the rewards are tremendous. With this in mind, we used TipRanks’ database to zero in on only the penny stocks that have received bullish support from the analyst community. We found two that are backed by enough analysts to earn a “Strong Buy” consensus rating. Not to mention each offers up massive upside potential. ADMA Biologics (ADMA) We'll start with ADMA Biologics, an end-to-end biopharmaceutical company, which develops and commercializes blood plasma-derived products that can be used to treat infectious disease – and more important, to help prevent such diseases in the first place. ADMA, in 2020, saw the expansion of two products for the treatment of primary humoral immunodeficiency (PI). These products, Asceniv and Bivigam, are both derived from human blood plasma and deliver immune globulin to the patient through intravenous injection. In any business, success is measured in cash. ADMA achieved that, reporting a 44% year-over-year increase in total revenues for 2020, with the top line reaching $42.2 million. This was driven by increased sales of the company’s main intra-venous immune globulin (IVIG) products. Going forward, ADMA recognizes the underlying fact of its products – that they are derived from human blood products, and so are dependent on voluntary donations. The company currently has 7 plasma collection centers in operation, with COVID safeguards in place, and plans to open two more this year. Longer-term expansion plans include opening 10 additional centers by 2024. Currently going for $1.55 apiece, the pros on the Street think that ADMA's share price presents investors with an attractive entry point. Among the bulls is Maxim's 5-star analyst, Jason McCarthy, who sees a clear path forward for the company. “Management is executing on its strategy and off the heels of a positive, but COVID-19 impacted year, ADMA is poised for a breakout in 2021. Multiple initiatives should drive revenue and margin acceleration. In particular, ASCENIV’s new J-code and multiple manufacturing initiatives, including the new fill-finish machine and BIVIGAM’s capacity expansion to ~4,400 L, should drive sales and margin acceleration in 2H21," McCarthy opined. The analyst added, "There is valuation disconnect between the company’s plasma collection facilities + sales potential vs. the market cap, in our opinion. Grifols recently acquired 25 US-based plasma centers for ~$370M, valuing each center at ~$15M. ADMA has 7 centers in various stages of development/ approval, and is planning to expand to 10 fully operational by 2024. The company is already on a ~$55M run-rate, with accelerating sales and on pace for potentially ~$250M by 2024. Management is executing, and we believe the intrinsic value of the plasma facilities and approved products already should exceed the company’s market cap." In line with these expectations, McCarthy rates ADMA a Buy, and his $6 price target indicates confidence in a robust 266% growth potential for the coming year. (To watch McCarthy’s track record, click here) It’s clear from the analyst consensus that McCarthy is no outlier on this stock. ADMA has 4 recent reviews on record, and all are to Buy, making the consensus rating a unanimous Strong Buy. The $7.67 average price target is even more bullish than McCarthy’s, and suggests a one-year upside of 393%. (See ADMA stock analysis on TipRanks) Catalyst Biosciences (CBIO) The next stock we’ll look at, Catalyst Biosciences, works in the biopharmaceutical industry, where it researches unmet needs in rare disorders of the complement and coagulation systems. The company has a protease engineering platform, and its hemostasis development program includes two late-stage clinical tracks. The complement pipeline is still in preclinical development, and includes four separate drug candidates. Catalyst has seen a major milestone back in December last year, when the FDA granted Fast Track Designation for the the company’s most advanced pipeline product, marzeptacog alfa (activated), or MarzAA. The fast track designation will allow Catalyst more opportunities to work hand in hand with the FDA in MarzAA's development and could involve a priority review if it meets its endpoints in studies. MarzAA is a next-gen engineered coagulation Factor VIIa for the treatment of episodic bleeding in hemophilia patients. It is currently entering a Phase 3 trial with plans to enroll 60 subjects. The company anticipates sending its final report to the Data and Safety Monitoring Board in mid-2022. CBIO's strong pipeline has scored it substantial praise from Piper Sandler analyst Tyler Van Buren. "In our view, the catalytic power of the company's protease platform continues to be underappreciated due to lack of familiarity. First up in 2021, we look forward to data from the MarzAA Phase III trial, which could support a 2023 approval. The Phase I/II trial in Glanzmann thrombasthenia (1,600+ patients) and other indications will also get underway. For Catalyst's complement-targeting proteases, we expect an observational trial to begin shortly in CFI deficiency, which should provide a bolus of patients to enroll in a Phase I for CB 4332 next year. There is also significant upside potential from expansion of CB 4332 into other indications, and from the rest of the complement franchise which includes CB2782-PEG, a novel anti-C3 protease for dry AMD, and other C4b degraders," Van Buren wrote. With the active development program in mind, the analyst summed up, “Bottom line, we… recommend that investors accumulate shares ahead of the upcoming study initiations and clinical readouts throughout the year.” Those bullish comments back the analyst’s Overweight (i.e., Buy) rating on the stock. His price target, of $15, implies an upside of 229% for the next 12 months. (To watch Van Buren’s track record, click here) What does the rest of the Street think about CBIO's prospects? It turns out that other analysts agree with Van Buren. The stock received 4 Buys in the last three months compared to no Holds or Sells, making the consensus rating a Strong Buy. CBIO shares are currently trading at $4.69, and the $18.50 average price target brings the upside potential to 296%. (See CBIO stock analysis on TipRanks) To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.